Talphera Q2 2026 net loss $4.3M; nafamostat CRRT study 75% enrolled

TALPHERA, INC.

Net loss $4.3M ($0.06/share) vs $3.5M loss ($0.10/share) in Q2 2025; cash/investments $17.1M at June 30, 2026.
R&D and SG&A expenses combined $3.9M vs $3.7M in Q2 2025, driven by higher Niyad development costs.
NEPHRO CRRT study of nafamostat 75% enrolled, expected to complete in 2026; all target clinical sites activated.
KDIGO 2026 draft guidelines cite nafamostat as acceptable CRRT anticoagulant; updated market research estimates 200k annual U.S. CRRT procedures (+21%).
Regained Nasdaq compliance with $1 bid price rule.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.